文献速递淋巴瘤

复发弥漫大B细胞淋巴瘤注册试验入选标准差异显著限制临床适用性

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.
PubMed 文献 · Br J Haematol · 2026-05-15

该研究分析七项复发或难治性弥漫大B细胞淋巴瘤注册试验的入选标准,并将其应用于澳大利亚180例接受标准治疗的现实世界队列。试验中位入选标准39条(范围31-45),320例次复发中52%不符合任何试验标准,且无患者满足全部七项试验条件;全因死亡在不符合与符合至少一项试验的患者间无差异(p=0.97)。

要点

  • 七项注册试验中位入选标准39条,范围31-45,患者与疾病领域差异显著。
  • 320例次复发中52%不符合任何试验,无患者满足全部七项试验标准。
  • 不符合任何试验与符合至少一项试验的患者全因死亡无差异(p=0.97)。

核心结论

  • 入选标准的高度异质性使多数现实世界患者被排除在试验之外,限制试验结果的普适性。

研究设计与样本

  • 分析七项复发或难治性弥漫大B细胞淋巴瘤注册试验的入选标准,并 hypothetical 应用于澳大利亚180例接受标准治疗的现实世界队列。

主要发现

  • 试验要求中位39条入选标准(范围31-45),患者与疾病领域间差异显著。
  • 320例次复发(中位1次,范围1-8)中52%不符合任何试验,无患者满足全部七项试验标准。
  • 入选率从4%(SADAL)至22%(ZUMA-1)不等。
  • 不符合任何试验与符合至少一项试验的患者全因死亡无差异(p=0.97)。
  • 两组中位无进展生存期与注册研究相当。

关键数值与推荐

  • 试验中位入选标准39条(范围31-45)。
  • 320例次复发中52%不符合任何试验标准,无患者满足全部七项试验标准。
  • 入选率范围4%(SADAL)至22%(ZUMA-1)。
  • 排除常见原因包括既往治疗限制、洗脱期要求和器官功能障碍。

临床怎么用

  • 解读注册试验结果时需考虑入选标准对现实世界患者的排除效应。
  • 试验入选标准需更包容和标准化以提高结果普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic options for relapsed or refractory diffuse large B-cell lymphoma (rDLBCL) have expanded following accelerated approvals based largely on surrogate end-points, yet confirmatory studies have not consistently reproduced these benefits across all agents, and outcomes for many patients remain poor. Restrictive and heterogeneous eligibility criteria further limit generalisability of trial findings to routine populations. We examined eligibility criteria across seven registrational rDLBCL trials and applied them hypothetically to a real-world cohort of 180 patients treated in Australia with standard-of-care therapies. The trials required a median of 39 criteria (range 31-45), with marked variability across patient and disease domains. The greatest discordance related to prior lines of therapy, definitions of measurable disease and organ function parameters. Among 320 patient relapses (median 1, range 1-8), 52% were ineligible for any trial and no patient met criteria for all seven. Eligibility ranged from 4% (SADAL) to 22% (ZUMA-1). Common reasons for exclusion were limits on prior therapy, washout requirements and organ dysfunction. Overall survival did not differ between patients ineligible for all trials and those eligible for at least one (p = 0.97). Median progression-free survival (PFS) was comparable to registrational studies in both groups. Substantial eligibility heterogeneity excludes most real-world patients, limiting trial generalisability and supporting the need for more inclusive, standardised frameworks.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Goodall E, Palmer J, Martynchyk A, et al. Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice. Br J Haematol. 2026. PMID: 42141736. doi:10.1111/bjh.70550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。